Streetbeat News

Analyst Ratings

CVNA

Carvana shares rose after Stephens & Co. initiated coverage with an Overweight rating and a $190 price target.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:57 pm

APA

JP Morgan analyst Arun Jayaram maintains a Neutral rating on APA Corporation (NASDAQ:APA) and lowers the price target from $36 to $27.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:56 pm

AR

JP Morgan analyst Arun Jayaram maintains an Overweight rating on Antero Resources but lowers the price target from $37 to $30.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:55 pm

SEAT

DA Davidson analyst Tom White maintains a Buy rating on Vivid Seats (NASDAQ:SEAT) but lowers the price target from $6.5 to $6.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:52 pm

SEAT

Canaccord Genuity has maintained a Buy rating on Vivid Seats but lowered the price target from $8 to $7.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:49 pm

PLTR

Palantir Technologies (NYSE:PLTR) shares are trading flat as the company hosts its fifth AIPCon event. The stock has risen over 15% this week following its inclusion in the S&P 500 index. B of A Securities raised its price target for PLTR from $30 to $50, citing potential benefits from increased institutional investment. The stock is currently trading above its 200-day moving average, indicating a bullish trend.

Portfolio Pulse from Erica Kollmann

September 12, 2024 | 3:48 pm

VNO

Goldman Sachs analyst Caitlin Burrows maintains a Sell rating on Vornado Realty (NYSE:VNO) but raises the price target from $21.5 to $23.75.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:46 pm

VRDN

Goldman Sachs analyst Richard Law has maintained a Buy rating on Viridian Therapeutics and increased the price target from $25 to $31.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:45 pm

PTGX

HC Wainwright & Co. has maintained a Buy rating on Protagonist Therapeutics and raised the price target from $40 to $50, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:38 pm

WOOF

Goldman Sachs analyst Kate McShane maintains a Buy rating on Petco Health and Wellness (NASDAQ:WOOF) but lowers the price target from $5 to $4.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:35 pm